Answers are grounded in this paper and cite their sources.
Recent advances in tissue engineering have positioned cardiac patch devices as a promising strategy to restore heart function and structure following myocardial infarction (MI). However, many existing patches are limited by the absence of vascular networks and insufficient biomolecular signals to effectively promote cardiomyocyte (CM) regeneration. In this study, we address these limitations by incorporating follistatin-like 1 (FSTL1) and CHIR99021 (CHIR) into a 3D bioprinted vascularized cardiac patch. The pro-proliferative effects of FSTL1 and CHIR on human induced pluripotent stem cell (hiPSC)-derived CMs were validated in vitro using 2D cultures, 3D hydrogel casts, and 3D bioprinted constructs. The synergistic impact of FSTL1 and CHIR was further evaluated in a rat model of acute MI. Treatment with the CHIR+FSTL1-loaded cardiac patch led to significant improvement in cardiac function and reduced fibrosis. Enhanced angiogenesis and increased CM proliferation were also observed following patch treatment. By integrating 3D bioprinting with targeted regenerative cues, this engineered cardiac patch presents strong therapeutic potential for myocardial repair.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: